JoomFish-Language Selection
|
The Pulmonary-Allergy Drugs Advisory Committee is meeting today to review InterMune's NDA for pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis. As a result, trading of the company's stock has been halted. InterMune release |
Partenaires sponsors
Sanofi Aventis
Merck & Co
Groupe LFB
Santeos
Partenaires
Commission Européenne
Commission Européenne
Agence Nationale de la recherche
HAS
Inserm
Ministère de l'enseignement supérieur et de la recherche
Angels santé
Actelion pharmaceuticals
Biopharmaceutiques
Cerenis therapeutics
CISS
Fovea pharmaceuticals
IMS Health
Janssen Cilag
Paris Biotech Santé
Pharmaceutiques
Px therapeutics
Biocitech
Actulabo
Hungarian Biotechnology
